Anavex Life Sciences Corp. (AVXL) Income Statement
AVXL FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsAVXL revenue and net income
AVXL growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AVXL quarterly EPS vs estimates
Anavex Life Sciences beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 24, 2026 (estimate $-0.11).
AVXL income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | $0 | $0 | $1,252 |
| Gross profit | — | — | — | — | — | — | — | $0 | $0 | −$1,252 |
| Research & development | $37.6M | $41.8M | $43.7M | $37.9M | $33.0M | $25.2M | $22.3M | $13.3M | $10.7M | $7.3M |
| Sales, general & admin | $13.8M | $11.0M | $12.2M | $13.1M | $9.1M | $5.9M | $6.8M | $6.1M | $5.1M | $8.3M |
| Total operating expenses | $51.4M | $52.9M | $55.8M | $51.0M | $42.0M | $31.1M | $28.8M | $19.2M | $15.5M | $14.9M |
| Operating income | −$51.4M | −$52.9M | −$47.5M | −$51.0M | −$42.0M | −$31.1M | −$28.8M | −$19.2M | −$15.5M | −$15.6M |
| Interest income | $4.7M | $7.3M | $6.5M | $946,988 | $26,261 | $179,973 | $207,280 | $255,092 | $88,098 | $11,322 |
| Interest expense | $0 | $0 | $964,000 | $946,988 | $4.0M | $4.8M | $151,133 | $30,943 | $0 | $11.3M |
| Income before taxes | −$46.4M | −$43.0M | −$47.5M | −$47.6M | −$37.6M | −$30.6M | −$26.2M | −$17.4M | −$13.4M | −$14.7M |
| Income taxes | −$648,000 | −$2.3M | −$7,000 | $358,000 | $268,000 | −$4.4M | $82,181 | $72,746 | $59,607 | $29,615 |
| Net income | −$46.4M | −$43.0M | −$47.5M | −$48.0M | −$37.9M | −$26.3M | −$26.3M | −$17.5M | −$13.5M | −$14.7M |
| EBITDA | −$46.4M | −$43.0M | −$47.5M | −$47.6M | −$37.6M | −$31.1M | −$28.9M | −$19.1M | −$15.6M | −$15.0M |
| EPS (diluted) | −$0.54 | −$0.52 | −$0.60 | −$0.62 | −$0.53 | −$0.45 | −$0.54 | −$0.39 | −$0.33 | −$0.42 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $4.1M | $4.2M | $4.7M | $7.3M | $10.0M | $9.9M | $10.4M | $11.6M | $11.8M | $9.7M | $8.7M | $10.1M |
| Sales, general & admin | $2.4M | $2.3M | $2.1M | $3.5M | $4.5M | $2.6M | $3.1M | $2.8M | $2.8M | $2.9M | $2.7M | $2.6M |
| Total operating expenses | $6.5M | $6.5M | $6.8M | $10.8M | $14.5M | $12.5M | $13.6M | $14.3M | $14.6M | $12.6M | $11.4M | $12.7M |
| Operating income | −$6.5M | −$6.5M | −$6.8M | −$10.8M | −$14.5M | −$12.5M | −$13.6M | −$14.3M | −$14.6M | −$12.6M | −$11.4M | −$12.7M |
| Interest income | $1.1M | $1.1M | $1.1M | $999,000 | $1.1M | $1.2M | $1.4M | $1.8M | $1.8M | $1.8M | $2.0M | $2.0M |
| Interest expense | — | — | — | — | — | — | — | $0 | $0 | $0 | — | $1.1M |
| Income before taxes | −$3.2M | −$5.4M | −$5.7M | −$9.8M | −$13.2M | −$11.2M | −$12.1M | −$11.7M | −$12.2M | −$10.5M | −$8.6M | −$10.2M |
| Income taxes | $18,000 | −$27,000 | $18,000 | — | −$127,000 | −$96,000 | −$412,000 | −$124,000 | −$67,000 | $105,000 | $85,000 | −$63,954 |
| Net income | −$3.2M | −$5.3M | −$5.7M | −$9.8M | −$13.2M | −$11.2M | −$12.1M | −$11.6M | −$12.2M | −$10.5M | −$8.6M | −$10.1M |
| EBITDA | −$3.2M | −$6.5M | −$5.7M | −$6.5M | −$14.3M | −$12.4M | −$13.6M | −$11.7M | −$14.1M | −$12.2M | −$8.6M | −$10.2M |
| EPS (diluted) | $0.08 | −$0.13 | −$0.06 | −$0.11 | −$0.16 | −$0.13 | −$0.14 | −$0.14 | −$0.14 | −$0.13 | −$0.11 | −$0.12 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AVXL's financial statements (latest annual report filed November 25, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AVXL financial results
Anavex Life Sciences reported no revenue in fiscal year 2025 (ended September 30, 2025). It had a net loss of $46.4 million. Diluted earnings per share came to −$0.54.
See the AVXL stock overview for the latest quote and news, or the AVXL chart for price history and technical indicators.
AVXL income statement FAQ
Does Anavex Life Sciences have revenue?
Anavex Life Sciences reported no revenue for fiscal year 2025, which ended on September 30, 2025.
Is Anavex Life Sciences profitable?
No. Anavex Life Sciences reported a net loss of $46.4 million in fiscal 2025.
How much does Anavex Life Sciences spend on research and development?
Anavex Life Sciences spent $37.6 million on research and development in fiscal 2025.
What are Anavex Life Sciences's earnings per share?
Anavex Life Sciences earned $-0.54 per diluted share in fiscal 2025, compared with $-0.52 a year earlier.
When will Anavex Life Sciences report its next earnings?
Anavex Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 24, 2026 before the market opens.
When does Anavex Life Sciences's fiscal year end?
Anavex Life Sciences's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on November 25, 2025.